tetano
Editor, Senior Moderator
Cancer
. 2023 Mar 15.
doi: 10.1002/cncr.34726. Online ahead of print.
Rate of COVID-19 vaccination among patients with cancer who tested positive for severe acute respiratory syndrome-coronavirus 2: Analysis of the American Society of Clinical Oncology Registry
Dax Kurbegov[SUP] 1 [/SUP], Suanna S Bruinooge[SUP] 2 [/SUP], Xiudong Jennifer Lei[SUP] 2 [/SUP], M Kelsey Kirkwood[SUP] 2 [/SUP], Natalie Dickson[SUP] 3 [/SUP], Trupti Hattiangadi[SUP] 4 [/SUP], Kathryn F Mileham[SUP] 5 [/SUP], Alicia Patrick[SUP] 5 [/SUP], Jen Hanley Williams[SUP] 2 [/SUP], Melinda Kaltenbaugh[SUP] 2 [/SUP], Julie R Gralow[SUP] 2 [/SUP], Elizabeth Garrett-Mayer[SUP] 2 [/SUP]
Affiliations
Abstract
Background: The availability of safe and effective COVID-19 vaccines has enabled protections against serious COVID-19 outcomes, which are particularly important for patients with cancer. The American Society of Clinical Oncology Registry enabled the study of COVID-19 vaccine uptake in patients with cancer who were positive for severe acute respiratory syndrome-coronavirus 2.
Methods: Medical oncology practices entered data on patients who were in cancer treatment. The cohort included patients who had severe acute respiratory syndrome-coronavirus 2 infection in 2020 and had visits and vaccine data after December 31, 2020. The primary end point was the time to first vaccination from January 1, 2021. Cumulative incidence estimates and Cox regression with death as a competing risk were used to describe the time to vaccine uptake and factors associated with vaccine receipt.
Results: The cohort included 1155 patients from 56 practices. Among 690 patients who received the first vaccine dose, 92% received the second dose. The median time to vaccine was 99 days. After adjustment, older patients were associated with a higher likelihood of vaccination compared with patients younger than 50 years in January through March 2021, and age exhibited a linear effect, with older patients showing higher rates of vaccination. Metastatic solid tumors (hazard ratio
, 0.85; 95% confidence interval [CI], 0.73-0.98) or non-B-cell hematologic malignancies (HR, 0.71; 95% CI, 0.54-0.93) compared with nonmetastatic solid tumors, and any comorbidity (HR, 0.83; 95% CI, 0.73-0.95) compared with no comorbidity, were associated with lower vaccination rates. Area-level social determinants of health (lower education attainment and higher unemployment rates) were associated with lower vaccination rates.
Conclusions: Patient age, cancer type, comorbidity, area-level education attainment, and unemployment rates were associated with differential vaccine uptake rates. These findings should inform strategies to communicate about vaccine safety and efficacy to patients with cancer.
Keywords: coronavirus disease 2019 (COVID-19); neoplasms; registries; severe acute respiratory syndrome-coronavirus 2 (SARS-CoV-2); vaccination.
. 2023 Mar 15.
doi: 10.1002/cncr.34726. Online ahead of print.
Rate of COVID-19 vaccination among patients with cancer who tested positive for severe acute respiratory syndrome-coronavirus 2: Analysis of the American Society of Clinical Oncology Registry
Dax Kurbegov[SUP] 1 [/SUP], Suanna S Bruinooge[SUP] 2 [/SUP], Xiudong Jennifer Lei[SUP] 2 [/SUP], M Kelsey Kirkwood[SUP] 2 [/SUP], Natalie Dickson[SUP] 3 [/SUP], Trupti Hattiangadi[SUP] 4 [/SUP], Kathryn F Mileham[SUP] 5 [/SUP], Alicia Patrick[SUP] 5 [/SUP], Jen Hanley Williams[SUP] 2 [/SUP], Melinda Kaltenbaugh[SUP] 2 [/SUP], Julie R Gralow[SUP] 2 [/SUP], Elizabeth Garrett-Mayer[SUP] 2 [/SUP]
Affiliations
- PMID: 36920457
- DOI: 10.1002/cncr.34726
Abstract
Background: The availability of safe and effective COVID-19 vaccines has enabled protections against serious COVID-19 outcomes, which are particularly important for patients with cancer. The American Society of Clinical Oncology Registry enabled the study of COVID-19 vaccine uptake in patients with cancer who were positive for severe acute respiratory syndrome-coronavirus 2.
Methods: Medical oncology practices entered data on patients who were in cancer treatment. The cohort included patients who had severe acute respiratory syndrome-coronavirus 2 infection in 2020 and had visits and vaccine data after December 31, 2020. The primary end point was the time to first vaccination from January 1, 2021. Cumulative incidence estimates and Cox regression with death as a competing risk were used to describe the time to vaccine uptake and factors associated with vaccine receipt.
Results: The cohort included 1155 patients from 56 practices. Among 690 patients who received the first vaccine dose, 92% received the second dose. The median time to vaccine was 99 days. After adjustment, older patients were associated with a higher likelihood of vaccination compared with patients younger than 50 years in January through March 2021, and age exhibited a linear effect, with older patients showing higher rates of vaccination. Metastatic solid tumors (hazard ratio
, 0.85; 95% confidence interval [CI], 0.73-0.98) or non-B-cell hematologic malignancies (HR, 0.71; 95% CI, 0.54-0.93) compared with nonmetastatic solid tumors, and any comorbidity (HR, 0.83; 95% CI, 0.73-0.95) compared with no comorbidity, were associated with lower vaccination rates. Area-level social determinants of health (lower education attainment and higher unemployment rates) were associated with lower vaccination rates.
Conclusions: Patient age, cancer type, comorbidity, area-level education attainment, and unemployment rates were associated with differential vaccine uptake rates. These findings should inform strategies to communicate about vaccine safety and efficacy to patients with cancer.
Keywords: coronavirus disease 2019 (COVID-19); neoplasms; registries; severe acute respiratory syndrome-coronavirus 2 (SARS-CoV-2); vaccination.